Liraglutide for Metabolic Syndrome

Phase 4
Recruiting
Led By Zhenqi Liu, MD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ace inhibitor
Alpha-adrenergic antagonist
Must not have
Be younger than 18 years old
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up24weeks
Awards & highlights
Pivotal Trial
No Placebo-Only Group
All Individual Drugs Already Approved
Drug Has Already Been Approved

Study Summary

This trial is studying whether exercise, liraglutide, or both can improve cardiac and skeletal muscle function in people with Metabolic Syndrome.

Eligible Conditions
  • Metabolic Syndrome

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Select...
You are currently taking Ace inhibitors medication.
Select...
You are taking medication for high blood pressure that affects alpha receptors.
Select...
You have at least three of the five risk factors for metabolic syndrome as defined by the National Cholesterol Education Program Adult Treatment Panel III.
Select...
You are taking beta blockers.
Select...
You are taking medication called calcium channel blockers.
Select...
This is not a complete criterion. Please provide more information about the screening criteria related to statins.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Microvascular Blood Volume - change from baseline
Secondary outcome measures
Augmentation Index - change from baseline
Flow Mediated Dilation
Insulin Sensitivity - change from baseline
+2 more

Side effects data

From 2017 Phase 4 trial • 100 Patients • NCT02014740
29%
nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Liraglutide
Metformin

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Liraglutide AloneExperimental Treatment1 Intervention
24 weeks of treatment
Group II: Exercise AloneExperimental Treatment1 Intervention
24 weeks of treatment
Group III: Exercise + LiraglutideExperimental Treatment1 Intervention
24 weeks f treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide
FDA approved

Find a site

Who is running the clinical trial?

University of VirginiaLead Sponsor
721 Previous Clinical Trials
1,567,442 Total Patients Enrolled
5 Trials studying Metabolic Syndrome
478 Patients Enrolled for Metabolic Syndrome
National Institutes of Health (NIH)NIH
2,611 Previous Clinical Trials
6,804,810 Total Patients Enrolled
11 Trials studying Metabolic Syndrome
2,107 Patients Enrolled for Metabolic Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,258 Previous Clinical Trials
4,200,366 Total Patients Enrolled
35 Trials studying Metabolic Syndrome
2,872 Patients Enrolled for Metabolic Syndrome
Zhenqi Liu, MDPrincipal Investigator - Division of Endocrinology and Metabolism, University of Virginia
UVA-HealthSouth Rehabilitation Hospital, University of Virginia Medical Center
Hunan Medical University (Medical School)
University Of Va Medical Center (Residency)
3 Previous Clinical Trials
94 Total Patients Enrolled

Media Library

Exercise training Clinical Trial Eligibility Overview. Trial Name: NCT04575844 — Phase 4
Metabolic Syndrome Patient Testimony for trial: Trial Name: NCT04575844 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to participate in this research?

"This research program is looking to enrol 80 individuals with metabolic syndrome between 21 and 60 years old. To qualify, they must have an increased waist circumference (≥102 cm in men; ≥88 cm in women), BMI >25 and ≤35 kg/m2, triglycerides at least 150 mg/dl, HDL-cholesterol under 40mg/dl for males or 50 mg/dl for females, systolic blood pressure of 130 mmHg or higher OR diastolic blood pressure 85mmHg+, fasting glucose levels greater than 100 mg/dL, and be on stable doses of ACE inhibitors and beta blockers for a"

Answered by AI

Is the cutoff age for eligibility in this trial beyond eighty years?

"The qualifications for this study restrict applicants to those between 21 and 60 years old. By contrast, there are 388 trials available for minors, while 1070 exist for seniors."

Answered by AI

Is this research experiment currently enrolling participants?

"Clinicaltrials.gov declares that this clinical trial is actively searching for participants, with the initial posting made on November 1st 2020 and most recently updated July 15th 2022."

Answered by AI

What conditions does Liraglutide typically serve to ameliorate?

"Liraglutide is an effective therapeutic option for those suffering from exercise-induced symptoms, inadequate control on monotherapy treatments, and cardiovascular risk reduction."

Answered by AI

How large is the population sample size for this research undertaking?

"Affirmative. Clinicaltrials.gov archives demonstrate that this trial, which was first publicized on November 1st 2020, is currently recruiting individuals for participation. 80 subjects are required to be enrolled from one medical centre."

Answered by AI

Has the U.S. Food and Drug Administration given its stamp of approval to Liraglutide?

"There is ample evidence suggesting liraglutide's safety, thus it was given a score of 3 on our scale. This treatment has already been approved and released to the public in this Phase 4 trial."

Answered by AI

Who else is applying?

What state do they live in?
Illinois
Alabama
Virginia
How old are they?
18 - 65
What site did they apply to?
University of Virginia
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I’m using Saxenda and losing weight. I also sense that it’s helping control urinary incontenence. I want to learn more and also be part of study. I want to know scientific facts about impact of Saxenda and exercise long term to control obesity.
Patient
Recent research and studies
~27 spots leftby Apr 2025